Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
Open Access
- 1 September 2020
- journal article
- review article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 26 (9), 1559-1566
- https://doi.org/10.1016/j.bbmt.2020.04.016
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaLeukemia & Lymphoma, 2012
- Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myelomaCancer, 2011
- Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myelomaLeukemia & Lymphoma, 2011
- Treatment of multiple myelomaNature Reviews Clinical Oncology, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyHaematologica, 2010
- Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321Journal of Clinical Oncology, 2006
- High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMABlood, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999